Ronninge, Sweden

Nicolaas Schipper


Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2020-2021

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Nicolaas Schipper: Innovator in Pharmaceutical Formulations

Introduction

Nicolaas Schipper is a notable inventor based in Ronninge, Sweden, recognized for his contributions to the field of pharmaceuticals. With two patents to his name, Schipper has focused on developing innovative formulations that address complex medical conditions, showcasing his dedication to enhancing healthcare.

Latest Patents

One of Schipper's latest patents is centered on a pharmaceutical formulation of 3-alpha-ethynyl-3-beta-hydroxyandrostan-17-one oxime. This formulation includes 0.1-10% by weight of the active compound and a vehicle comprising 45-100% of a monoester, optional diester up to 51%, and triester up to about 10%. Additionally, this invention claims to offer a method for treating medical conditions such as hypersomnia and hepatic encephalopathy through its unique pharmaceutical formulation, aiming to significantly improve patient outcomes.

Career Highlights

Nicolaas Schipper is currently associated with Umecrine Cognition AB, a company engaged in advancing cognitive health through innovative pharmaceuticals. His work in this organization exemplifies the cutting-edge research and development that characterizes the modern pharmaceutical industry.

Collaborations

Throughout his career, Schipper has collaborated with esteemed colleagues including Paul Alhadeff and Magnus Doverskog. These collaborations have undoubtedly enriched his research and contributed to the successful development of his patents, reflecting the importance of teamwork in scientific innovation.

Conclusion

In conclusion, Nicolaas Schipper stands out as an influential inventor in the pharmaceutical domain. His creations, particularly in the formulation of novel compounds, not only enhance our understanding of medical treatments but also pave the way for future innovations in healthcare. As he continues to work with Umecrine Cognition AB and his talented colleagues, his contributions will likely have a lasting impact on the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…